CARLSBAD, Calif., March 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that recent clinical data suggest that REMUNE(TM), its immune-based therapy to treat HIV infection, may induce HIV immunity when used as a combination therapy with other antiviral drugs or when used alone as a monotherapy. The data from multiple clinical trials were presented at ``An International Conference on HIV Vaccines -- An Annual Update -- 2000'' sponsored by the Thai Ministry of Public Health in Bangkok, Thailand.
``While antiviral drug therapy has been very beneficial to HIV patients in keeping viral load in check, it has not generally proven to help rebuild the immune system, which is ravaged by the virus. A common theme among the trial results reported today suggests that REMUNE may help to restore immune function to these patients. In fact, it is the T helper cells -- the very immune cells that are destroyed by the virus -- that appear to re-establish after treatment with REMUNE,'' said Dr. Vina Churdboonchart, principal investigator for the trial in Thailand. ``This is important because an emerging consensus among HIV researchers is that immune health may be the key to controlling HIV infection in the long term.'' Dr. Churdboonchart stated that she is currently completing all documentation necessary for submission to the Thai Minister of Public Health for commercial approval of REMUNE in Thailand.
Dr. Sukeepaisarncharoen, a clinician in the Thai study, presented data obtained during the follow-up period after the trial was completed on the same subset of patients. He noted that 87% (59/68) of those patients tested 48 weeks after the trial's end had stable (39 patients) or significantly decreased (20 patients) amounts of HIV in the bloodstream, commonly referred to as viral load. Furthermore, the decrease or stabilization of viral load was associated with a sustained increase in number of CD4 helper T cells as well as increased body weight
Ich schätze ,das IMNR heute losschiessen wird!